ATROVENT HFA
SAMA MDI
Ipratropium bromide · Boehringer Ingelheim
Active Medication & Mechanism
- Ipratropium bromide SAMA17 mcg per actuation
Short-acting muscarinic antagonist (anticholinergic). Blocks vagally mediated reflexes by antagonizing M3 receptors on bronchial smooth muscle, inhibiting bronchoconstriction and mucus secretion.
FDA-Approved Dosing — Strength × Indication
Strength Regimen COPDAsthma
17 mcg
2 inhalations four times a day → 136 mcg (8 inhalations)
FDA Approved
Maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema. Maximum 12 inhalations in 24 hours.
Not Approved
Atrovent HFA is not indicated for asthma, though it may be used off-label. Not FDA-approved for asthma.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
17 mcg 2 inhalations four times a day → 136 mcg (8 inhalations)
COPD FDA Approved
Maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema. Maximum 12 inhalations in 24 hours.
Asthma Not Approved
Atrovent HFA is not indicated for asthma, though it may be used off-label. Not FDA-approved for asthma.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. ATROVENT HFA is not indicated for initial treatment of acute bronchospasm requiring rapid-response rescue therapy.